- Home
- KEN vs TVTX Comparison
KEN vs TVTX Comparison
Compare KEN & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEN
- TVTX
- Stock Information
- Founded
- KEN 2014
- TVTX 2008
- Country
- KEN Singapore
- TVTX United States
- Employees
- KEN N/A
- TVTX N/A
- Industry
- KEN Electric Utilities: Central
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KEN Utilities
- TVTX Health Care
- Exchange
- KEN Nasdaq
- TVTX Nasdaq
- Market Cap
- KEN 1.5B
- TVTX 1.5B
- IPO Year
- KEN N/A
- TVTX N/A
- Fundamental
- Price
- KEN $33.21
- TVTX $19.46
- Analyst Decision
- KEN
- TVTX Buy
- Analyst Count
- KEN 0
- TVTX 12
- Target Price
- KEN N/A
- TVTX $24.58
- AVG Volume (30 Days)
- KEN 14.6K
- TVTX 1.2M
- Earning Date
- KEN 12-05-2024
- TVTX 02-13-2025
- Dividend Yield
- KEN 11.42%
- TVTX N/A
- EPS Growth
- KEN N/A
- TVTX N/A
- EPS
- KEN 3.23
- TVTX N/A
- Revenue
- KEN $742,796,000.00
- TVTX $203,447,000.00
- Revenue This Year
- KEN N/A
- TVTX $62.37
- Revenue Next Year
- KEN N/A
- TVTX $61.74
- P/E Ratio
- KEN $10.17
- TVTX N/A
- Revenue Growth
- KEN 8.29
- TVTX 57.08
- 52 Week Low
- KEN $19.63
- TVTX $5.12
- 52 Week High
- KEN $34.33
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- KEN 63.08
- TVTX 59.31
- Support Level
- KEN $31.30
- TVTX $16.80
- Resistance Level
- KEN $33.59
- TVTX $18.76
- Average True Range (ATR)
- KEN 0.82
- TVTX 0.95
- MACD
- KEN 0.09
- TVTX 0.09
- Stochastic Oscillator
- KEN 68.18
- TVTX 89.86
About KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented, businesses. The company's operating segments include OPC; CPV Group; and ZIM. It generates maximum revenue from the OPC segment. OPC operates in the Israeli electricity generation sector, including initiating, developing, constructing, and operating power plants and selling and supplying electricity. Geographically, it derives a majority of its revenue from Israel.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.